Thermo Fisher Unveils Integrated Biologics Platform

Got story updates? Submit your updates here. ›

Thermo Fisher Scientific, a leading life sciences company, has launched an integrated platform designed to streamline and accelerate the development of biologic drugs and therapies. The new offering combines Thermo Fisher's expertise in analytical instruments, software, and services to provide a comprehensive solution for biopharmaceutical companies.

Why it matters

The launch of this integrated platform by Thermo Fisher reflects the growing importance of biologics in the pharmaceutical industry. Biologics, which are derived from living organisms, have become increasingly crucial in the development of innovative treatments for a wide range of diseases. By offering an integrated solution, Thermo Fisher aims to help its customers bring these life-saving therapies to market more efficiently.

The details

The new platform from Thermo Fisher includes a range of analytical instruments, software, and services designed to support the entire biologics development lifecycle, from early-stage research to commercial manufacturing. The platform integrates Thermo Fisher's expertise in areas such as mass spectrometry, chromatography, and cell analysis to provide a seamless workflow for biopharmaceutical companies.

• Thermo Fisher Scientific announced the launch of the integrated platform on April 1, 2026.

What they’re saying

What’s next

Thermo Fisher plans to showcase the new integrated platform at the upcoming BIO International Convention in June 2026, where the company will demonstrate its capabilities and how it can benefit biopharmaceutical companies.